What is the Promise of Nicotinergic Compounds in Schizophrenia Treatment?

References

• Wong AH , Van TolHH. Schizophrenia: from phenomenology to neurobiology. Neurosci. Biobehav. Rev.27 (3), 269–306 (2003).
   PubMed Web of Science ®Google Scholar
• Leweke FM , OdorferTM, BumbJM. Medical needs in the treatment of psychotic disorders. Handb. Exp. Pharmacol. (212), 165–185 (2012).
   PubMedGoogle Scholar
• Young JW , GeyerMA. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem. Pharmacol.86 (8), 1122–1132 (2013).
   PubMed Web of Science ®Google Scholar
• Jones CK , ByunN, BubserM. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology37 (1), 16–42 (2012).
   PubMed Web of Science ®Google Scholar
• Severance EG , YolkenRH. Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. Genes Brain Behav.7 (1), 37–45 (2008).
   PubMed Web of Science ®Google Scholar
• Freedman R , HallM, AdlerLE, LeonardS. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry38 (1), 22–33 (1995).
   PubMed Web of Science ®Google Scholar
• Levin ED , McclernonFJ, RezvaniAH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl.)184 (3–4), 523–539 (2006).
   PubMed Web of Science ®Google Scholar
• Beinat C , BanisterSD, HerreraM, LawV, KassiouM. The therapeutic potential of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs29 (7), 529–542 (2015).
   PubMed Web of Science ®Google Scholar
• Olincy A , HarrisJG, JohnsonLLet al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry63 (6), 630–638 (2006).
   PubMed Web of Science ®Google Scholar
• Freedman R , OlincyA, BuchananRWet al. Initial Phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry165 (8), 1040–1047 (2008).
   PubMed Web of Science ®Google Scholar
• Umbricht D , KeefeRS, MurraySet al. A randomized, placebo-controlled study investigating the nicotinic alpha7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology39 (7), 1568–1577 (2014).
   PubMed Web of Science ®Google Scholar
• Prickaerts J , Van GoethemNP, ChesworthRet al. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology62 (2), 1099–1110 (2012).
   PubMed Web of Science ®Google Scholar
• Preskorn SH , GawrylM, DgetluckN, PalfreymanM, BauerLO, HiltDC. Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J. Psychiatr. Pract.20 (1), 12–24 (2014).
   PubMed Web of Science ®Google Scholar
• Winterer G , GallinatJ, BrinkmeyerJet al. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology64, 197–204 (2013).
   PubMed Web of Science ®Google Scholar
• Rowe AR , MercerL, CasettiVet al. Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia. J. Psychopharmacol.29 (2), 197–211 (2015).
   PubMed Web of Science ®Google Scholar
• Dunbar GC , KuchibhatlaRV, LeeG, Group T-aCS. A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment. J. Psychopharmacol.25 (8), 1020–1029 (2011).
   PubMed Web of Science ®Google Scholar
• Velligan D , BrennerR, SicuroFet al. Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophr. Res.134 (1), 59–64 (2012).
   PubMed Web of Science ®Google Scholar
• Hong LE , ThakerGK, McmahonRPet al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry68 (12), 1195–1206 (2011).
   PubMed Web of Science ®Google Scholar
• Waldo MC , WoodwardL, AdlerLE. Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study. Psychiatry Res.175 (1–2), 179–180 (2010).
   PubMed Web of Science ®Google Scholar
• Dineley KT , PandyaAA, YakelJL. Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol. Sci.36 (2), 96–108 (2015).
   PubMed Web of Science ®Google Scholar